Albany Molecular Research, Inc. (AMRI) To Announce Second Quarter Results
The audio webcast will be available live via the Internet and can be accessed on the company's website at www.amriglobal.com .
Albany Molecular Research Director Ambra Thomas E. Phd D Sells 20,000 Shares
Albany Molecular Research Director Ambra Thomas E. Phd D unloaded 20,000 shares of the stock on the open market in a transaction that occurred on Thursday, July 10th.
Customer Interaction Solutions
Analysts Review Releases Notes on Alere, AMRI, Anika Therapeutics,...
On July 4, Analysts Review released its analysts' notes regarding Alere, Albany Molecular Research, Anika Therapeutics, Nektar Therapeutics and Sangamo Biosciences.
Investor's Business Daily
Albany Molecular's Oso Buy Seen Boosting Earnings
In a report issued Monday morning, Sterne Agee analyst Greg Bolan said he is "officially incorporating our estimates for accretion" into Albany's earnings for this year and next year.
AMRI Completes Acquisition of Oso Biopharmaceuticals Manufacturing
AMRI today announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC. The transaction is consistent with AMRI's strategy to be the preeminent supplier of custom and complex drug product development and manufacturing services to the pharmaceutical industry.
Albany Molecular Research Reaches New 12-Month High at $21.14
Albany Molecular Research hit a new 52-week high on Tuesday , American Banking News.com reports.